Page 9 - Nasdaq Mltx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq mltx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Mltx Today - Breaking & Trending Today

MoonLake Immunotherapeutics (NASDAQ:MLTX) Earns Equal Weight Rating from Analysts at Barclays

Barclays initiated coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) in a report published on Thursday, The Fly reports. The firm issued an equal weight rating and a $28.00 price objective on the stock. Several other equities research analysts also recently commented on MLTX. 22nd Century Group reissued a reiterates rating on shares […] ....

United States , Bihua Chen , Moonlake Immunotherapeutics , Renaissance Technologies , Ensign Peak Advisors Inc , America Corp , Century Group , Goldman Sachs Group Inc , Geode Capital Management , Cantor Fitzgerald , Get Rating , Moderate Buy , Capital Management , Peak Advisors Inc , Goldman Sachs Group , Nasdaq Mltx , Initiated Coverage , Barclays Plc ,

MoonLake Immunotherapeutics (NASDAQ:MLTX) Now Covered by Analysts at Barclays

Barclays assumed coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) in a research report report published on Thursday morning, The Fly reports. The brokerage issued an equal weight rating and a $28.00 target price on the stock. A number of other brokerages also recently issued reports on MLTX. Wedbush initiated coverage on MoonLake […] ....

Moonlake Immunotherapeutics , Bihua Chen , Cantor Fitzgerald , Citadel Advisors , Century Group , Pricet Rowe Associates Inc , Hermes Inc , Get Rating , Moderate Buy , Nasdaq Mltx , Initiated Coverage , Barclays Plc ,

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Buy" from Analysts

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) has earned a consensus rating of “Buy” from the twelve analysts that are covering the company, Marketbeat.com reports. Eleven research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year […] ....

United States , Bihua Chen , Moonlake Immunotherapeutics , Goldman Sachs Group Inc , Renaissance Technologies , Garnier Co , Cantor Fitzgerald , America Corp , Geode Capital Management , Securities Exchange Commission , Get Rating , Exchange Commission , Sachs Group , Capital Management , Two Sigma Investments , Nasdaq Mltx ,

Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target at $25.29

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) has received an average recommendation of “Buy” from the twelve brokerages that are covering the stock, Marketbeat Ratings reports. Eleven investment analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have covered the stock in the last year is $25.29. A […] ....

United States , Bihua Chen , Moonlake Immunotherapeutics , America Corp , Renaissance Technologies , Goldman Sachs Group Inc , Geode Capital Management , Garnier Co , Moonlake Immunotherapeutics Company Profile , Get Rating , Marketbeat Ratings , Sachs Group , Capital Management , Two Sigma Investments , Nasdaq Mltx ,

MoonLake Immunotherapeutics (NASDAQ:MLTX) Hits New 12-Month High at $30.30

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating)’s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $30.30 and last traded at $30.10, with a volume of 358283 shares traded. The stock had previously closed at $28.54. Analyst Upgrades and Downgrades MLTX has been the subject of […] ....

United States , Moonlake Immunotherapeutics , Bihua Chen , Garnier Co , Renaissance Technologies , Goldman Sachs Group Inc , America Corp , Century Group , Geode Capital Management , Get Rating , Capital Management , Sachs Group , Ally Bridge Group , Nasdaq Mltx ,